Jochen Antel

This inventor holds 18 USPTO granted patents and 2 published patent applications and 3 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Solvay Pharmaceuticals, Gmbh, Abbott Products Gmbh. Active years: 1997-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jochen Antel. Retrieved from https://idiyas.com/inventor/jochen-antel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 2)

% Patents Active = 44.4

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 6.2

ph-index = 3

Forward Citations = 116(Granted Patents)

Location History:

Muender, DE (2009)
Bad Muender, DE (1997 - 2010)
Bad Münder, DE (2010)
Münder, DE (2011)

Company Filing History:

17 out of 77

Solvay Pharmaceuticals, Gmbh

Years Active: 1997-2011

Loading Chart...

Areas of Expertise:

Cannabinoid Receptor Antagonists

Obesity Treatment

Pharmaceutical Formulations

Piperidine Compounds

NK1 Antagonists

BRS-3 Agonists

Alkyl Carbamate

Isomerically Pure Compounds

Urea Derivatives

Piperazine Derivatives

Benzazepine Compounds

Non-Peptidic Modulators

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8058264 - Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions (2011-11-15),

2. 7772225 - N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions (2010-08-10),

3. 7767692 - 1-amidomethylcarbonyl-piperidine compounds, methods and intermediate products for the production thereof and pharmaceutical formulations containing said compounds (2010-08-03),

4. 7763607 - Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators (2010-07-27),

5. 7592344 - NK1 and NK2-antagonists and compositions and methods of using the same (2009-09-22),

6. 7547708 - N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof (2009-06-16),

7. 7282325 - Method of preparing pharmaceutical compositions (2007-10-16),

8. 7244743 - Non-peptidic BRS-3 agonists (2007-07-17),

9. 7238470 - Method of treating or inhibiting obesity (2007-07-03),

10. 7074822 - Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them (2006-07-11),

11. 6946243 - Method of identifying compounds suitable for treatment and/or prophylaxis of obesity (2005-09-20),

12. 6930207 - Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment (2005-08-16),

13. 6900322 - Method for stereochemically controlled production of isomerically pure highly substituted azacyclic compounds (2005-05-31),

14. 6770649 - 1-[1-(hetero)aryl-1-perhydroxyalkylmethyl]-piperazine compounds, process for their preparation and pharmaceutical compositions containing them (2004-08-03),

15. 6040303 - 7-phenyl-1, 4-diazepane compounds, process for their preparation, and (2000-03-21),

Title: The Innovative Contributions of Jochen Antel

Introduction

Jochen Antel, an accomplished inventor based in Bad Muender, Germany, holds an impressive portfolio of 18 patents. His pioneering work primarily focuses on pharmaceutical innovations aimed at treating obesity and related health conditions. Antel's innovative thinking has led to significant advancements in the field of medical therapies.

Latest Patents

Among Jochen Antel’s latest patents is a groundbreaking invention pertaining to pharmaceutical compositions that combine CB1 cannabinoid receptor antagonists and potassium channel openers for the effective treatment of obesity and associated conditions. This novel approach describes a combination therapy that addresses diabetes mellitus type I and II, alongside metabolic syndrome and other secondary diseases. By utilizing a blend of potassium channel openers and cannabinoid receptor antagonists, this innovative treatment provides a dual-action mechanism beneficial to patients.

Another significant patent involves N-sulfamoyl-piperidineamides, which are designed to treat or inhibit obesity and its related complications. This invention encompasses novel compounds and their physiologically acceptable salts, highlighting their efficacy in pharmaceutical compositions aimed at combating obesity and its comorbidities.

Career Highlights

Jochen Antel's career includes significant contributions while working with reputable companies like Solvay Pharmaceuticals GmbH and Abbott Products GmbH. His experiences at these organizations have enriched his expertise in pharmaceutical development and innovation.

Collaborations

Throughout his career, Antel has collaborated with notable professionals, including Holger Sann and Harald Waldeck, enhancing the collaborative spirit in his research endeavors. These partnerships have likely played a crucial role in the successful development of his patented innovations.

Conclusion

In summary, Jochen Antel's contributions to pharmaceutical innovations, particularly in treating obesity and diabetes, have made him a notable figure in the field of medical research. His inventions, characterized by their dual-action therapies, hold promise for improving health outcomes for many individuals grappling with these conditions. As he continues to pave the way for future advancements, Antel's work will undoubtedly remain influential in the realm of pharmaceutical sciences.

Profile summary based on public USPTO records.